Citizens analyst Jonathan Wolleben downgraded Quince Therapeutics (QNCX) to Market Perform from Outperform.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics down 88% after reopening for trading
- Quince Therapeutics trading resumes
- Quince down 14% after NEAT study endpoint did not reach statistical significance
- Quince Therapeutics to cease clinical development of eDSP
- Quince Therapeutics says Phase 3 NEAT trial of eDSP did not meet endpoints